Literature DB >> 11395545

Contrasting pharmacological ETB receptor blockade with genetic ETB deficiency in renal responses to big ET-1.

D M Pollock1.   

Abstract

Renal clearance studies were conducted to determine the role of ET(B) receptors in the renal response to big endothelin-1 (big ET-1). Two series of experiments were conducted on Inactin-anesthetized rats to contrast acute pharmacological blockade of ET(B) receptors vs. genetic ET(B) receptor deficiency. In the first series, Sprague-Dawley rats were given either ET(B)-selective antagonist, A-192621, or vehicle (0.9% NaCl) prior to infusion of big ET-1 (10 pmol.kg(-1).min(-1)) for 60 min. A-192621 significantly increased baseline mean arterial pressure (MAP; 102 +/- 4 vs. 141 +/- 6 mmHg, P < 0.05) and urine flow rate (0.5 +/- 0.1 vs. 1.3 +/- 0.2 microl/min, P < 0.05) without any effect on glomerular filtration rate (GFR) or effective renal plasma flow (ERPF). Big ET-1 significantly increased MAP in both groups but to a higher level in rats given antagonist (120 +/- 6 vs. 169 +/- 6 mmHg, P < 0.05). Big ET-1 increased urine flow in control rats but decreased in rats given antagonist. GFR and ERPF were decreased in rats given big ET-1, an effect that was exaggerated by ET(B) blockade. Another series of experiments examined the response to big ET-1 in rats lacking functional renal ET(B) receptors, known as spotting lethal (sl) rats. Surprisingly, rats heterozygous (sl/+) for ET(B) receptor deficiency had a significantly higher baseline MAP compared with homozygous (sl/sl) rats (134 +/- 6 vs. 112 +/- 7 mmHg, P < 0.05), although other variables were similar. Big ET-1 produced no significant change in MAP in either group. Urine flow, GFR, and ERPF were significantly decreased in both groups, although these changes were much larger in sl/sl rats. These experiments indicate that the ET(B) receptor plays an important role in limiting the renal hemodynamic response to big ET-1. Furthermore, the diuretic actions of big ET-1 require a functional ET(B) receptor.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395545     DOI: 10.1152/physiolgenomics.2001.6.1.39

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  5 in total

1.  Somatostatin coupling to adenylyl cyclase activity in the mouse retina.

Authors:  Barbara Pavan; Sara Fiorini; Massimo Dal Monte; Laura Lunghi; Carla Biondi; Paola Bagnoli; Davide Cervia
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-08-12       Impact factor: 3.000

Review 2.  Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease.

Authors:  Markus P Schneider; Erika I Boesen; David M Pollock
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 3.  Endothelin-1 and the kidney--beyond BP.

Authors:  Neeraj Dhaun; David J Webb; David C Kluth
Journal:  Br J Pharmacol       Date:  2012-10       Impact factor: 8.739

4.  Stromal endothelin B receptor-deficiency inhibits breast cancer growth and metastasis.

Authors:  Claudia Binder; Thorsten Hagemann; Swetlana Sperling; Matthias Schulz; Tobias Pukrop; Matthew J Grimshaw; Hannelore Ehrenreich
Journal:  Mol Cancer Ther       Date:  2009-08-11       Impact factor: 6.261

5.  Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists.

Authors:  Stephanie W Watts; Gregory D Fink; Carrie A Northcott; James J Galligan
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.